Immatics (IMTX) Competitors $7.80 -0.01 (-0.13%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMTX vs. IMVT, RYTM, APLS, MLTX, AGIO, DYN, VRNA, PTCT, BHC, and EWTXShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Agios Pharmaceuticals (AGIO), Dyne Therapeutics (DYN), Verona Pharma (VRNA), PTC Therapeutics (PTCT), Bausch Health Companies (BHC), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Immunovant Rhythm Pharmaceuticals Apellis Pharmaceuticals MoonLake Immunotherapeutics Agios Pharmaceuticals Dyne Therapeutics Verona Pharma PTC Therapeutics Bausch Health Companies Edgewise Therapeutics Immunovant (NASDAQ:IMVT) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking. Which has stronger valuation and earnings, IMVT or IMTX? Immatics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$259.34M-$2.22-11.79Immatics$70.87M13.14-$104.98M-$0.89-8.76 Which has more volatility and risk, IMVT or IMTX? Immunovant has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Is IMVT or IMTX more profitable? Immunovant has a net margin of 0.00% compared to Immatics' net margin of -103.99%. Immatics' return on equity of -23.34% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -56.40% -52.03% Immatics -103.99%-23.34%-13.22% Do analysts rate IMVT or IMTX? Immunovant currently has a consensus price target of $48.10, indicating a potential upside of 83.80%. Immatics has a consensus price target of $16.67, indicating a potential upside of 113.68%. Given Immatics' higher possible upside, analysts clearly believe Immatics is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor IMVT or IMTX? In the previous week, Immatics had 14 more articles in the media than Immunovant. MarketBeat recorded 15 mentions for Immatics and 1 mentions for Immunovant. Immunovant's average media sentiment score of 0.90 beat Immatics' score of 0.25 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in IMVT or IMTX? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 5.9% of Immunovant shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor IMVT or IMTX? Immunovant received 93 more outperform votes than Immatics when rated by MarketBeat users. Likewise, 78.21% of users gave Immunovant an outperform vote while only 74.36% of users gave Immatics an outperform vote. CompanyUnderperformOutperformImmunovantOutperform Votes12278.21% Underperform Votes3421.79% ImmaticsOutperform Votes2974.36% Underperform Votes1025.64% SummaryImmatics beats Immunovant on 10 of the 16 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$930.98M$2.94B$5.05B$8.87BDividend YieldN/A1.89%4.97%4.06%P/E Ratio-8.7621.3797.3414.18Price / Sales13.14382.101,218.4289.42Price / CashN/A160.1133.5132.79Price / Book2.714.195.805.12Net Income-$104.98M-$41.63M$119.07M$225.99M7 Day Performance-8.56%-4.73%-1.83%-1.32%1 Month Performance-18.92%-6.53%-3.64%0.60%1 Year Performance-2.86%25.63%31.62%26.23% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.0118 of 5 stars$7.80-0.1%$16.67+113.7%-9.2%$930.98M$70.87M-8.76260Analyst ForecastNews CoverageIMVTImmunovant1.5467 of 5 stars$26.17+3.8%$48.10+83.8%-22.6%$3.70BN/A0.00120RYTMRhythm Pharmaceuticals2.8994 of 5 stars$59.36-1.0%$62.30+5.0%+78.0%$3.69B$77.43M0.00140Analyst ForecastAPLSApellis Pharmaceuticals4.5376 of 5 stars$27.49-5.2%$51.06+85.7%-44.5%$3.42B$396.59M-13.54702MLTXMoonLake Immunotherapeutics3.2689 of 5 stars$49.82+1.0%$79.00+58.6%+16.8%$3.15BN/A0.002AGIOAgios Pharmaceuticals3.3113 of 5 stars$54.62+0.4%$52.33-4.2%+154.0%$3.10B$32.87M4.81390DYNDyne Therapeutics3.3831 of 5 stars$29.99+1.0%$51.40+71.4%+181.6%$3.05BN/A-8.42100Insider TradeAnalyst RevisionVRNAVerona Pharma2.5968 of 5 stars$38.85+2.0%$43.83+12.8%+163.7%$3.04B$460,000.000.0030Positive NewsPTCTPTC Therapeutics2.5538 of 5 stars$41.96+6.6%$42.00+0.1%+89.3%$3.04B$937.82M0.001,410Analyst DowngradeBHCBausch Health Companies3.4347 of 5 stars$8.20+0.1%$7.75-5.4%+16.3%$3.01B$8.76B-17.0720,270Positive NewsEWTXEdgewise Therapeutics1.7269 of 5 stars$31.95+1.4%$38.40+20.2%+396.9%$2.98BN/A0.0060 Related Companies and Tools Related Companies Immunovant Competitors Rhythm Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Agios Pharmaceuticals Competitors Dyne Therapeutics Competitors Verona Pharma Competitors PTC Therapeutics Competitors Bausch Health Companies Competitors Edgewise Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
